Breaking News Instant updates and real-time market news.

NVS

Novartis

$89.59

0.62 (0.70%)

05:56
06/14/19
06/14
05:56
06/14/19
05:56

Novartis: follow-up data from ENESTfreedom, ENESTop trials show sustained TFR

Long-term follow-up data from the ongoing, pivotal open-label ENESTfreedom and ENESTop trials showed sustained treatment-free remission, or TFR, after stopping frontline and second-line Tasigna therapy in eligible adult patients with Philadelphia chromosome-positive, or Ph+, chronic myeloid leukemia, or CML, in the chronic phase, or CP. Separate data demonstrate promising results for asciminib, an investigational allosteric BCR-ABL inhibitor, in combination with three different tyrosine kinase inhibitors, or TKIs, in heavily pre-treated Ph+ CML-CP patients.

NVS Novartis
$89.59

0.62 (0.70%)

05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.
06/03/19
06/03/19
DOWNGRADE

Perform
Aduro Biotech downgraded to Perform on lack of catalysts at Oppenheimer
As previously reported, Oppenheimer analyst Mark Breidenbach downgraded Aduro Biotech (ADRO) to Perform from Outperform given the company's lack of near-term catalysts. The analyst notes that Aduro's partner Novartis (NVS) presented initial clinical results from an ongoing Phase 1b trial of ADU-S100 in combination with spartalizumab in advanced tumors at ASCO. Given the pretreatment history of these patients, he cannot state with confidence that the responses observed were dependent on ADUS100, and the trial data suggests dosing has not yet been fully optimized. As Novartis continues to evaluate the STING agonist, Breidenbach anticipates an extended development timeline.

TODAY'S FREE FLY STORIES

FTNT

Fortinet

$76.12

-0.82 (-1.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Upgrade
Fortinet rating change  »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

POST

Post Holdings

$104.28

0.075 (0.07%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Post Holdings narrows FY19 adjusted EBITDA view $1.2B-$1.22B from $1.2B-$1.24B »

Post Holdings provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMUX

Immunic

$9.71

0.04 (0.41%)

07:23
06/24/19
06/24
07:23
06/24/19
07:23
Hot Stocks
Immunic to present unpublished IMU-838 data at GIIDS »

Immunic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

PSTI

Pluristem

$0.57

-0.0142 (-2.43%)

07:21
06/24/19
06/24
07:21
06/24/19
07:21
Hot Stocks
Pluristem appoints Yaky Yanay as sole CEO »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$6.57

-0.19 (-2.81%)

07:20
06/24/19
06/24
07:20
06/24/19
07:20
Conference/Events
Pfenex management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Oct

INNT

Innovate Biopharmaceuticals

$1.23

-0.025 (-2.00%)

, CGIX

Cancer Genetics

$0.17

-0.0033 (-1.89%)

07:20
06/24/19
06/24
07:20
06/24/19
07:20
Hot Stocks
Innovate Biopharmaceuticals appoints ED Sitar as CFO »

Innovate…

INNT

Innovate Biopharmaceuticals

$1.23

-0.025 (-2.00%)

CGIX

Cancer Genetics

$0.17

-0.0033 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$57.07

-0.54 (-0.94%)

07:18
06/24/19
06/24
07:18
06/24/19
07:18
Conference/Events
NuVasive management to meet with BTIG »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

07:15
06/24/19
06/24
07:15
06/24/19
07:15
General news
FX Update: The dollar has started the week on a soft footing »

FX Update: The dollar has…

DAN

Dana

$17.94

0.05 (0.28%)

07:14
06/24/19
06/24
07:14
06/24/19
07:14
Hot Stocks
Dana announces reduction of pension liabilities »

Dana announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTRN

Materion

$67.06

-0.54 (-0.80%)

07:14
06/24/19
06/24
07:14
06/24/19
07:14
Conference/Events
Materion management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 25

    Sep

CGC

Canopy Growth

$40.20

-3.495 (-8.00%)

07:13
06/24/19
06/24
07:13
06/24/19
07:13
Hot Stocks
Canopy Growth adds substantial production capacity in Canada »

Canopy Growth is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPLX

MPLX

$32.46

0.58 (1.82%)

07:12
06/24/19
06/24
07:12
06/24/19
07:12
Conference/Events
MPLX management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

MDR

McDermott

$8.35

0.14 (1.71%)

07:12
06/24/19
06/24
07:12
06/24/19
07:12
Hot Stocks
McDermott awarded large offshore EPCI contract from Saudi Aramco »

McDermott announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$29.98

0.2 (0.67%)

07:10
06/24/19
06/24
07:10
06/24/19
07:10
Hot Stocks
Axalta Coating announces Chairman Charlie Shaver resigns, Mark Garrett succeeds »

Axalta Coating announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORV

Correvio

$2.27

-0.13 (-5.42%)

07:09
06/24/19
06/24
07:09
06/24/19
07:09
Hot Stocks
Correvio resubmits Brinavess NDA to FDA »

Correvio announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

07:07
06/24/19
06/24
07:07
06/24/19
07:07
Hot Stocks
Bristol-Myers: CheckMate -459 study did not reach pre-specified primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 16

    Sep

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

, CELG

Celgene

$98.92

0.75 (0.76%)

07:05
06/24/19
06/24
07:05
06/24/19
07:05
Hot Stocks
Bristol-Myers plans Otezla sale to get FTC Celgene clearance »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

CELG

Celgene

$98.92

0.75 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

, CELG

Celgene

$98.92

0.75 (0.76%)

07:03
06/24/19
06/24
07:03
06/24/19
07:03
Hot Stocks
Breaking Hot Stocks news story on Bristol-Myers, Celgene »

Bristol-Myers plans…

BMY

Bristol-Myers

$49.36

0.46 (0.94%)

CELG

Celgene

$98.92

0.75 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ATNX

Athenex

$17.95

-0.06 (-0.33%)

07:02
06/24/19
06/24
07:02
06/24/19
07:02
Hot Stocks
Athenex announces FDA allowance of IND application for PT01 »

Athenex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSLR

Vivint Solar

$7.27

-0.15 (-2.02%)

07:00
06/24/19
06/24
07:00
06/24/19
07:00
Hot Stocks
Vivint Solar closes $100M in financing to install over 55 megawatts of systems »

Vivint Solar announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 20

    Aug

  • 21

    Aug

TWNK

Hostess Brands

$13.89

0.065 (0.47%)

06:59
06/24/19
06/24
06:59
06/24/19
06:59
Upgrade
Hostess Brands rating change  »

Hostess Brands upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$78.85

-0.79 (-0.99%)

06:57
06/24/19
06/24
06:57
06/24/19
06:57
Hot Stocks
Leidos awarded $49M HHS artificial intelligence contract »

Leidos has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LFUS

Littelfuse

$177.05

-3.11 (-1.73%)

06:56
06/24/19
06/24
06:56
06/24/19
06:56
Conference/Events
Littelfuse management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

SOL

ReneSola

$1.28

(0.00%)

06:54
06/24/19
06/24
06:54
06/24/19
06:54
Hot Stocks
ReneSola, X-Elio North America to develop solar projects in North America »

ReneSola announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ASIX

AdvanSix

$25.55

-0.8 (-3.04%)

06:51
06/24/19
06/24
06:51
06/24/19
06:51
Hot Stocks
AdvanSix sees $7M-$12M unfavorable impact in Q3 due to PES refinery fire »

AdvanSix said that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.